We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Part of Viatris Inc.
Clinical Trials
0
0 active
Approvals
12
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
NMPA
National Medical Products Administration
- Strides Pharma Science's Singapore subsidiary has received USFDA approval for Celecoxib Capsules in 100 mg, 200 mg, and 400 mg dosages, strengthening its anti-inflammatory portfolio. - The approved product is bioequivalent to Celebrex Capsules and will be manufactured at the company's Puducherry facility in India, addressing a market worth approximately $116 million. - Celecoxib, a selective COX-2 inhibitor, is widely prescribed for managing pain and inflammation associated with osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea.
